Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-02T21:49:51.311Z Has data issue: false hasContentIssue false
  • English
  • Français

Concomitant Treatment of Neuroleptic Malignant Syndrome and Psychosis

Published online by Cambridge University Press:  02 January 2018

Harry D. Goldwasser ,
James F. Hooper  and
Nicki M. Spears
Harry D. Goldwasser
Affiliation:
University of North Carolina
James F. Hooper*
Affiliation:
College of Community Health Sciences, University of Alabama
Nicki M. Spears
Affiliation:
University of Alabama School of Medicine
*
∗PO Box 6331, Tuscaloosa, AL 39487, USA
Get access Rights & Permissions [Opens in a new window]

Abstract

Two cases are presented in which psychotic patients with neuroleptic malignant syndrome were treated with bromocriptine and thioridazine simultaneously, with a resulting control of both problems. The authors feel that this method needs further study, in the light of the potentially large number of patients at risk for these illnesses. The use of creatinine phosphokinase level as an indicator of value in NMS is also discussed.

Type
Brief Reports
Information
The British Journal of Psychiatry , Volume 154 , Issue 1 , January 1989 , pp. 102 - 104
Copyright
Copyright © The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Addonizio, G., Susman, V. L. & Roth, S. D. (1986) Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. American Journal of Psychiatry, 143, 1587–1590.Google Scholar
Addonizio, G., & Susman, V. L. (1987) ECT as a treatment alternative for patients with symptoms of neuroleptic malignant syndrome. Journal of Clinical Psychiatry, 48, 102–105.Google Scholar
Allsop, P. & Twigley, A. J. (1987) The neuroleptic malignant syndrome. Anaesthesia, 42, 49–53.Google Scholar
Caroff, S. N. (1980) The neuroleptic malignant syndrome. Journal of Clinical Psychiatry, 41, 79–83.Google Scholar
Fogel, B. S. & Goldberg, R. J. (1985) Neuroleptic malignant syndrome (letter). New England Journal of Medicine, 313, 1292.Google Scholar
Guzé, B. H. & Baxter, L. R. Jr (1985) Neuroleptic malignant syndrome. New England Journal of Medicine, 313, 163–166.Google Scholar
Ingall, T. J. & Tennant, C. (1986) Neuroleptic malignant syndrome. Medical Journal of Australia, 145, 454–455.Google Scholar
Jann, M. W., Garrelts, J. C., Ereshefsky, L. et al (1984) Alternative drug therapies for mania: a literature review. Drug Intelligence in Clinical Pharmacy, 18, 577–589.Google Scholar
Kurlan, R., Hamill, R. & Shoulson, I. (1984) Neuroleptic malignant syndrome. Clinical Neuropharmacology, 7, 109–120.Google Scholar
Mueller, P. S. (1985) Neuroleptic malignant syndrome. Psychosomatics, 26, 654–662.Google Scholar
Pelonero, A. L., Levenson, J. L. & Silverman, J. J. (1985) Neuroleptic therapy following neuroleptic malignant syndrome. Psychosomatics, 26, 946–948.Google Scholar
Shalev, A., Hermesh, H., Aizengerg, D. et al (1985) Neuroleptic malignant syndrome (letter). New England Journal of Medicine, 313, 1292–1293.Google Scholar
Suhayl, D.-J., Hesselbrock, R., Mouradian, M. M. & Means, E. D. (1987) Bromocriptine treatment of neuroleptic malignant syndrome. Journal of Clinical Psychiatry, 48, 69–73.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.